BioSpace News Archive

Assertio Holdings, Inc., a leading commercial pharmaceutical company bringing differentiated products to patients, announced it has acquired Otrexup, a drug device combination single dose once weekly auto-injector, from Antares Pharma, Inc. in the Company’s first new product acquisition since 2015.

Antares Pharma, Inc., a specialty pharmaceutical company, announced the divestiture of OTREXUP® injection for the treatment of rheumatoid arthritis to a subsidiary of Assertio Holdings, Inc., a commercial pharmaceutical company, for a total cash consideration of $44.0 million inclusive of OTREXUP® WIP and finished inventory.

Helix BioPharma Corp., a clinical-stage biopharmaceutical company developing unique therapies in the field of immuno-oncology based on its proprietary technological platform DOS47, announced fiscal 2022 first quarter results for the period ending October 31, 2021.

Mesoblast Limited announced that it has received feedback from the US Food & Drug Administration’s Office of Tissues and Advanced Therapies on the Phase 3 program of rexlemestrocel-L in patients with chronic low back pain due to degenerative disc disease refractory to available therapies, including opioids.

Trinity Biotech plc announced results for the quarter ended September 30, 2021, the entry into a $81.25million loan facility to refinance the existing $99.9million of exchangeable senior notes issued by the Company’s subsidiary, Trinity Biotech Investment Limited, and exchange agreements for over 99.7% of the outstanding Notes, all subject to certain conditions precedent.

Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, announced the pricing of an underwritten public offering of 3,157,144 shares of its common stock, and to certain investors pre-funded warrants to purchase 1,142,856 shares of its common stock at an exercise price of $0.0001.

IACTA Pharmaceuticals, Inc. (“IACTA”), an innovation leader in ophthalmic therapeutics, and TALLC Corporation Inc. (“TALLC”), a pioneering ophthalmology company focused on the growing unmet needs of patients with corneal and retinal conditions, today announced that they are entering into a strategic collaboration and licensing agreement.

Asher Biotherapeutics, a biotechnology company developing precisely-targeted immunotherapies for cancer, autoimmune, and infectious diseases, provided an overview of its cis-targeting platform and growing pipeline of highly differentiated precision immunotherapies.

Spectrum Solutions, LLC today announced that COVID-19 RT-PCR saliva tests using the Spectrum SDNA-1000 for bio-sample collection will also successfully be able to detect the additional Omicron viral variant and its mutations.

1910 Genetics today announced that Jennifer Leeds, Ph.D., will join as an independent member of the company’s Board of Directors.